Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2013 - 2016)

Soleno Therapeutics (SLNO) reported Preferred Stock Liabilities of $13.0 for Q4 2016, down 100.0% quarter-over-quarter from $1.5 million in Q3 2014.

Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2013 - 2016) Analysis & Trends

Soleno Therapeutics (SLNO) has 3 years of Preferred Stock Liabilities data on file, last reported at $13.0 in Q4 2016.

Preferred Stock Liabilities for Q4 2016 came in at $13.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $13.0 (changed N/A YoY), and the FY2016 annual result was $13.0, changed N/A from the prior year.
Preferred Stock Liabilities declined to $13.0 in Q4 2016 per SLNO's latest filing, from $1.5 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $6.9 million in Q4 2013 and troughed at $13.0 in Q4 2016.
A 3-year average of $2.8 million and a median of $1.5 million in 2014 frame the typical range for Preferred Stock Liabilities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Soleno Therapeutics	2.76 Bn	2.51 Bn	93.41 Mn	-

Download Data